Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
The production of glucagon-like peptide 1 (GLP-1), an incretin hormone, has been shown to be abnormally low in patients with type 2 diabetes, suggesting that GLP-1 may be a contributor in the pathogenesis of the disease. New type 2 diabetic medications target incretin hormones in their mechanism of...
Saved in:
| Main Author: | Gail Mkele |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2013-12-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/3943 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01) -
Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01) -
Long-term use of dipeptyl peptidase-4 inhibitors suppresses systemic oxidative stress in rats with type 2 diabetes
by: S. S. Bolevich, et al.
Published: (2019-12-01) -
Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01) -
Deciphering new biomolecules, antioxidants, and human dipeptidyl Peptidase-4 inhibitor potential of green celery: Bioprospecting insights from molecular docking and in vitro investigation
by: Fan Maitri Aldian, et al.
Published: (2025-10-01)